X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12332) 12332
Publication (835) 835
Newspaper Article (617) 617
Book Review (169) 169
Newsletter (103) 103
Book / eBook (65) 65
Book Chapter (33) 33
Magazine Article (30) 30
Conference Proceeding (21) 21
Trade Publication Article (14) 14
Web Resource (7) 7
Data Set (5) 5
Report (5) 5
Paper (2) 2
Transcript (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10476) 10476
male (6296) 6296
female (6237) 6237
cytarabine - administration & dosage (5873) 5873
oncology (5162) 5162
middle aged (5138) 5138
adult (4934) 4934
antineoplastic combined chemotherapy protocols - therapeutic use (4723) 4723
hematology (4644) 4644
index medicus (4015) 4015
aged (3587) 3587
chemotherapy (3232) 3232
adolescent (2841) 2841
treatment outcome (2510) 2510
leukemia, myeloid, acute - drug therapy (2269) 2269
remission induction (2107) 2107
cancer (2069) 2069
leukemia (1818) 1818
antineoplastic combined chemotherapy protocols - adverse effects (1687) 1687
child (1602) 1602
antineoplastic combined chemotherapy protocols - administration & dosage (1579) 1579
prognosis (1568) 1568
cytarabine (1429) 1429
dose-response relationship, drug (1410) 1410
etoposide - administration & dosage (1364) 1364
therapy (1347) 1347
cyclophosphamide - administration & dosage (1334) 1334
daunorubicin - administration & dosage (1332) 1332
cytarabine - adverse effects (1311) 1311
cytarabine - therapeutic use (1304) 1304
animals (1269) 1269
vincristine - administration & dosage (1269) 1269
methotrexate - administration & dosage (1267) 1267
transplantation (1254) 1254
acute myelogenous leukemia (1250) 1250
disease-free survival (1230) 1230
combined modality therapy (1227) 1227
acute myeloid-leukemia (1155) 1155
child, preschool (1126) 1126
drug dosages (1107) 1107
acute disease (1087) 1087
recurrence (1058) 1058
care and treatment (1039) 1039
acute myeloid leukemia (1031) 1031
antineoplastic agents - administration & dosage (1017) 1017
survival rate (1013) 1013
research (1006) 1006
dosage and administration (997) 997
doxorubicin - administration & dosage (985) 985
drug administration schedule (972) 972
retrospective studies (967) 967
survival analysis (936) 936
antineoplastic agents - therapeutic use (900) 900
aged, 80 and over (895) 895
time factors (874) 874
follow-up studies (837) 837
young adult (831) 831
risk factors (819) 819
pharmacology & pharmacy (807) 807
lymphomas (787) 787
stem cells (784) 784
prednisone - administration & dosage (776) 776
drug therapy (746) 746
leukemia, myeloid, acute - mortality (739) 739
infant (730) 730
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (723) 723
health aspects (722) 722
leukemia, myeloid - drug therapy (715) 715
transplantation, autologous (715) 715
hematopoietic stem cell transplantation (708) 708
bone-marrow-transplantation (701) 701
high-dose cytarabine (696) 696
patients (696) 696
survival (694) 694
cytarabine - pharmacology (692) 692
clinical trials (690) 690
mice (680) 680
stem-cell transplantation (676) 676
immunology (661) 661
non-hodgkins-lymphoma (651) 651
cancer therapies (647) 647
mitoxantrone - administration & dosage (609) 609
salvage therapy (596) 596
bone marrow transplantation (589) 589
bone-marrow transplantation (588) 588
idarubicin - administration & dosage (587) 587
aml (582) 582
cytosine-arabinoside (581) 581
acute lymphoblastic-leukemia (578) 578
antimetabolites, antineoplastic - administration & dosage (574) 574
drug therapy, combination (562) 562
leukemia - drug therapy (560) 560
children (548) 548
lymphoma, non-hodgkin - drug therapy (547) 547
medicine & public health (541) 541
dexamethasone - administration & dosage (526) 526
rituximab (526) 526
prospective studies (525) 525
leukemia, myeloid, acute - pathology (523) 523
trial (509) 509
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (42) 42
Collection Dvlpm't (Acquisitions) - Closed Orders (7) 7
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Scarborough Hospital - Hospital Department (2) 2
Chemistry (A D Allen) - Reference (1) 1
Credit Valley Hospital - Reference (1) 1
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Reference (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Mt Sinai Hospital - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
UofT at Mississauga - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12684) 12684
German (120) 120
Russian (91) 91
French (90) 90
Polish (75) 75
Spanish (66) 66
Czech (16) 16
Hungarian (13) 13
Japanese (11) 11
Italian (10) 10
Chinese (9) 9
Portuguese (5) 5
Serbian (4) 4
Hebrew (3) 3
Danish (2) 2
Dutch (2) 2
Norwegian (2) 2
Slovak (2) 2
Turkish (2) 2
Arabic (1) 1
Croatian (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Hematology, ISSN 0361-8609, 01/2017, Volume 92, Issue 1, pp. 12 - 17
Acute myeloid leukemia (AML) patients with t (8;21) aberration often have favorable outcomes, however, relapse still occurs in 30–40% patients, with only... 
GENE-MUTATIONS | TRIAL | ADULT PATIENTS | PROGNOSTIC IMPACT | CORE-BINDING-FACTOR | ACUTE MYELOGENOUS LEUKEMIA | C-KIT | CUMULATIVE INCIDENCE | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | 1ST COMPLETE REMISSION | Chromosomes, Human, Pair 8 - genetics | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Consolidation Chemotherapy | Cytarabine - adverse effects | Dose-Response Relationship, Drug | Young Adult | Leukemia, Myeloid, Acute - drug therapy | Adult | Proto-Oncogene Proteins c-kit - genetics | Vidarabine - adverse effects | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Chromosomes, Human, Pair 21 - genetics | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Vidarabine - administration & dosage | Mutation | Leukemia, Myeloid, Acute - genetics | Antimitotic agents | Care and treatment | Patient education | Myelocytic leukemia | Analysis | Oncology, Experimental | Nonlymphoid leukemia | Dosage and administration | Research | Antineoplastic agents | Cancer | Leukemia | Medical prognosis
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1025 - 1036
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 11, pp. 1027 - 1036
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2010, Volume 16, Issue 21, pp. 5303 - 5311
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2013, Volume 88, Issue 11, pp. 961 - 966
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin,... 
PHASE-III TRIAL | SOUTHWEST-ONCOLOGY-GROUP | DOSE CYTOSINE-ARABINOSIDE | GROUP-B | ARA-C | DAUNORUBICIN | HEMATOLOGY | CANCER | CHEMOTHERAPY | MODULATION | INDUCTION TREATMENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Follow-Up Studies | Nausea - chemically induced | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Arabinonucleosides - administration & dosage | Idarubicin - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Idarubicin - administration & dosage | Adenine Nucleotides - administration & dosage | Idarubicin - therapeutic use | Drug Eruptions - etiology | Adenine Nucleotides - therapeutic use | Arabinonucleosides - adverse effects | Remission Induction | Arabinonucleosides - therapeutic use | Cytarabine - administration & dosage | Adenine Nucleotides - adverse effects | Induction Chemotherapy - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Pilot Projects | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Consolidation Chemotherapy - adverse effects | Anthracyclines | Drug therapy | Multivariate analysis | Leukemia | Index Medicus | AML | idarubicin | cytarabine | frontline therapy | clofarabine
Journal Article
Cancer, ISSN 0008-543X, 01/2013, Volume 119, Issue 1, pp. 90 - 98
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2010, Volume 150, Issue 2, pp. 200 - 208
Journal Article
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Infection - chemically induced | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article